

CSD/NSE&BSE/ESOP/2026-27  
Date: May 13, 2026

**To**  
**The Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400001**

**To**  
**The Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400051**

**Scrip Code: 530239**

**Scrip Symbol: SUVEN**

Dear Sir/Madam,

**Sub: Grant of Stock Options by the Nomination & Remuneration Committee of the Company**

.....

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Nomination & Remuneration Committee of the Suven Life Sciences Limited (“Company”) considered and approved the **Grant-III** of 1,33,200 Stock Options at its meeting held on 13th May, 2026 under the Suven Life Sciences Limited – Employee Stock Option Scheme 2020 (“SLSL ESOP 2020”) to the eligible employees of the Company.

The required information in compliance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure – 1**

This is for your information and records.

Thanking you,  
Yours faithfully,  
For **Suven Life Sciences Limited**

**K. Sangeetha Laxmi**  
Company Secretary and Compliance officer

Encl.: as above

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: info@suvan.com website: www.suvan.com

**Annexure 1**

| Sl. No.                 | Items of Disclosure  | Description  |                         |                        |             |                         |                        |             |                         |                        |             |
|-------------------------|--|--|-------------------------|------------------------|-------------|-------------------------|------------------------|-------------|-------------------------|------------------------|-------------|
| 1.                      | Brief details of options granted   | <b>Grant-III:</b> 1,33,200 Stock Options have been granted to the eligible employees of the Company, under the Scheme– “Suven Life Employee Stock Option Scheme 2020 (SLSL ESOP 2020)”.  |                         |                        |             |                         |                        |             |                         |                        |             |
| 2.                      | whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)      | Yes  |                         |                        |             |                         |                        |             |                         |                        |             |
| 3.                      | total number of shares covered by these options                                      | 1,33,200 Equity shares of ₹ 1/- each of the Company. Each stock option carries the right to apply for and be allotted 1 (one) equity share of face value of ₹ 1/- each of the Company.   |                         |                        |             |                         |                        |             |                         |                        |             |
| 4.                      | pricing formula  | The exercise price of each ESOP shall be ₹ 55/- per option   |                         |                        |             |                         |                        |             |                         |                        |             |
| 5.                      | options vested   | <p>All the options granted shall vest not earlier than minimum period of 1 (one) year.</p> <p>Vesting schedule to be as follows:</p> <table border="1"> <tbody> <tr> <td>1<sup>st</sup> Tranche</td> <td>40% of options granted</td> <td>13-May-2027</td> </tr> <tr> <td>2<sup>nd</sup> Tranche</td> <td>30% of options granted</td> <td>13-May-2028</td> </tr> <tr> <td>3<sup>rd</sup> Tranche</td> <td>30% of options granted</td> <td>13-May-2029</td> </tr> </tbody> </table> <p>The Nomination and Remuneration Committee may at its discretion, but subject to applicable laws, change the vesting schedule provided that such change is not detrimental in the interest of the employees.</p> | 1 <sup>st</sup> Tranche | 40% of options granted | 13-May-2027 | 2 <sup>nd</sup> Tranche | 30% of options granted | 13-May-2028 | 3 <sup>rd</sup> Tranche | 30% of options granted | 13-May-2029 |
| 1 <sup>st</sup> Tranche | 40% of options granted   | 13-May-2027  |                         |                        |             |                         |                        |             |                         |                        |             |
| 2 <sup>nd</sup> Tranche | 30% of options granted   | 13-May-2028  |                         |                        |             |                         |                        |             |                         |                        |             |
| 3 <sup>rd</sup> Tranche | 30% of options granted   | 13-May-2029  |                         |                        |             |                         |                        |             |                         |                        |             |
| 6.                      | time within which option may be exercised  | The exercise period shall be up to two (2) years from the date of vesting of Options.  |                         |                        |             |                         |                        |             |                         |                        |             |
| 7.                      | options exercised  | Nil  |                         |                        |             |                         |                        |             |                         |                        |             |
| 8.                      | money realized by exercise of options  | Nil  |                         |                        |             |                         |                        |             |                         |                        |             |
| 9.                      | the total number of shares arising as a result of exercise of option                 | Nil  |                         |                        |             |                         |                        |             |                         |                        |             |
| 10.                     | options lapsed   | Nil  |                         |                        |             |                         |                        |             |                         |                        |             |
| 11.                     | variation of terms of options  | The Board or Nomination and Remuneration Committee may, if it deems necessary, modify, change, vary, amend, suspend or terminate the SLSL ESOP 2020, subject to compliance with the applicable laws and regulations.   |                         |                        |             |                         |                        |             |                         |                        |             |
| 12.                     | brief details of significant terms   | Options granted under SLSL ESOP 2020 shall vest not earlier than minimum period of 1 (One) year.   |                         |                        |             |                         |                        |             |                         |                        |             |
| 13.                     | subsequent changes or cancellation or exercise of such options                       | NA   |                         |                        |             |                         |                        |             |                         |                        |             |
| 14.                     | diluted earnings per share pursuant to issue of equity shares on exercise of options | NA   |                         |                        |             |                         |                        |             |                         |                        |             |

## Suven Life Sciences Limited